|
Vaccine Detail
PSA/IL-2/GM-CSF Vaccine |
Vaccine Information |
- Vaccine Name: PSA/IL-2/GM-CSF Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007153
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- IL12
gene engineering:
- Type: Recombinant protein preparation
- Description: (Fujio et al., 2015)
- Detailed Gene Information: Click Here.
- GM-CSF (human)
gene engineering:
- Adjuvant:
- Preparation: SGE plasmid encoding a fusion protein of full-length human PAP and one of the cytokines (human GMCSF, IL2, IL4, IL7 or mouse GMCSF or IL4) were then constructed and used to express the recombinant PAP-fused cytokines (Fujio et al., 2015).
- Description: This is for Prostate Cancer (NCT02058680). A prostate cancer vaccine containing prostate specific antigen (PSA) combined with the cytokines, interleukin-2 (IL-2) and granulocyte macrophage-colony-stimulating factor (GM-CSF), with potential antineoplastic activity. Upon intradermal vaccination, PSA/IL-2/GM-CSF vaccine may activate the immune system to induce a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed by prostate cancer cells. IL-2 stimulates natural killer (NK) cells and cytotoxic T-cells against the PSA-expressing tumor cells. GM-CSF promotes antigen presentation to dendritic cells and further stimulates a tumor-specific cytotoxic T-lymphocyte (CTL) response (Onaitis et al., 2002; NCIT_C114289).
|
Host Response |
|
References |
Fujio et al., 2015: Fujio K, Watanabe M, Ueki H, Li SA, Kinoshita R, Ochiai K, Futami J, Watanabe T, Nasu Y, Kumon H. A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment. Oncology reports. 2015; 33(4); 1585-1592. [PubMed: 25632844].
NCIT_C114289: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114289]
NCT02058680: Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients (PSA) [https://clinicaltrials.gov/ct2/show/NCT02058680]
Onaitis et al., 2002: Onaitis M, Kalady MF, Pruitt S, Tyler DS. Dendritic cell gene therapy. Surgical oncology clinics of North America. 2002; 11(3); 645-660. [PubMed: 12487060].
|
|